Developer docs
API playgroundTry for free, no card

Search company profiles

Geneyx

Full company profile

uuid0002f9o

Namestring
Geneyx
Legal namestring
Geneyx Genomex Ltd.
Websiteurl
geneyx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Geneyx Genomex Ltd. is a privately-held Israeli health technology company that develops Geneyx Analysis, an AI-powered tertiary analysis platform for interpreting next-generation sequencing (NGS) data including whole genome sequencing, whole exome sequencing, gene panels, and microarrays. The platform combines automated bioinformatics pipelines with machine learning-based variant prioritization that integrates phenotypic data (HPO terms) and curated literature, alongside ACMG-compliant classification. It supports both short-read sequencing via the embedded Illumina DRAGEN secondary pipeline and long-read sequencing from PacBio HiFi and Oxford Nanopore, with extensions into multi-omics DNA+RNA analysis (via the SVDuo/Ocean Genomics/Omics Discoveries collaboration), methylation analysis, phasing, and a pharmacogenomics module covering 87 genes and 321+ drugs.

The company operates a subscription-based enterprise SaaS model with both cloud and on-premise deployment, sold primarily through direct field sales to hospitals, clinical diagnostic laboratories, and academic medical centers, supplemented by regional distributors covering EMEA, APAC, LATAM, the Middle East (via Digi7), and Africa (via Inqaba Biotec). Customers enter Master Software Subscription and Services Agreements with annual billing, and multiple relationships are documented at 4-6 year tenure, including IRCCS Bambino Gesù (Italy, extended 6 years), University of Hong Kong, and Hospital Universitari Son Espases. The platform holds ISO 13485:2016, ISO/IEC 27001:2022, ISO 27799:2016, HIPAA, GDPR, UK NHS Data Security and Protection Toolkit, and Cyber Essentials certifications — a regulatory stack required for clinical procurement.

Geneyx is integrated as the official tertiary analysis partner for Oxford Nanopore (EPI2ME), PacBio (Sequel II/IIe/Revio Compatible program), and Illumina (DRAGEN), and was selected into the Google AI First Accelerator in 2024. The company has raised $6.5 million in seed funding (November 2021, Capri + Accenture Ventures), maintains offices in Herzliya (HQ), Wilmington DE, and Heerlen (Netherlands), and serves approximately 2,000 active users analyzing 500,000+ clinical cases across 36 countries. It operates with a lean headcount of 11-50 employees.

Short descriptiontext

Geneyx is an Israeli healthtech company that provides an AI-powered tertiary analysis platform for interpreting next-generation sequencing data, serving hospitals, clinical diagnostic labs, and academic medical centers across 36+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHerzliya, Israel
HQ citystring
Herzliya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genomics software, NGS data analysis, variant interpretation platform, pharmacogenomics analysis, multi-omics interpretation
Industry5 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Genomics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Geneyx Analysis Software Subscriptions
TypeSubscription Recurring
Description

Geneyx generates revenue through software subscription agreements (Master Software Subscription and Services Agreement) for access to the Geneyx Analysis platform. Customers include hospitals, clinical diagnostic companies, and academic institutions. The platform is offered as a cloud-based SaaS solution with on-premise capability.

geneyx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Platform access with subscription-based pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / not publicly disclosed. Enterprise SaaS subscription model. Demo and trial options available.

geneyx.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Geneyx Analysis
Description

AI-Based Genetic Data Analysis and Interpretation Solution for WGS, WES, Gene Panels, and Microarrays.

geneyx.com
+3 more records
Core offering1 text field

Geneyx develops and sells Geneyx Analysis, an AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of next-generation sequencing (NGS) data — including whole-genome sequencing (WGS), whole-exome sequencing (WES), gene panels, microarrays, and long-read (PacBio HiFi, Oxford Nanopore) data. The platform automates variant annotation, ACMG-based classification, phenotypic prioritization, multi-omics (DNA + RNA + methylation) interpretation, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Hospitals report analyzing up to 15,000 samples/year with Geneyx Analysis, up from 400 samples/year before adoption
+2 more records
Product overview1 text field

Geneyx offers a unified platform architecture centered on Geneyx Analysis as the core product, complemented by specialized modules including Geneyx MultiOmics for integrated DNA/RNA/epigenetics analysis, Long-Read Analysis for PacBio and Oxford Nanopore sequencing data, and Geneyx Pharmacogenomics covering 87 genes and 321+ drugs. The SVDuo module (co-developed with Ocean/Omics Discoveries) enables combined DNA and RNA analysis for enhanced structural variant detection. Geneyx Clinical Apps provides clinical interpretation services. All products share a common AI-powered annotation and visualization engine within Geneyx Analysis, which serves as the central platform for variant prioritization, filtering, interpretation, and clinical reporting across all sequencing modalities.

Product and service6 records
1Geneyx Analysis
CategoryClinical Genomics SaaS Platform
Description

AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of NGS data (WGS, WES, gene panels, microarrays, and long-read). Automates variant annotation, ACMG classification, phenotypic prioritization, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.

2Geneyx MultiOmics
CategoryMulti-Omics Analysis
Description

Multi-omics analysis product that combines DNA, RNA, and epigenetics (methylation) data for enhanced variant detection and functional genomics interpretation, built jointly with Omics Discoveries.

3Long-Read Analysis
CategoryLong-Read Sequencing Analysis
Description

Long-read sequencing analysis product compatible with PacBio HiFi (Sequel II, IIe, Revio) and Oxford Nanopore data, supporting phasing, methylation analysis, and structural variant detection.

4Geneyx Pharmacogenomics
CategoryPharmacogenomics Interpretation
Description

Comprehensive pharmacogenomics workflow covering 87 genes and 321+ drugs, aligned with CPIC and PharmGKB levels; provides drug metabolism interpretations and clinical recommendations for 13 CPIC Level A/B genes affecting 68+ commonly prescribed drugs.

5Geneyx Clinical Apps
CategoryClinical Interpretation Services
Description

Clinical interpretation services that deliver accurate, compliant, and signed clinical reports for healthcare providers, including pharmacogenomics reporting.

6SVDuo
CategoryDNA-RNA Integrated Analysis
Description

Integrated DNA and RNA analysis software co-developed with Ocean Genomics/Omics Discoveries, designed to enhance genomic variant detection by revealing previously undetectable structural variants through combined DNA and RNA analysis.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-30
Description

Partnership between Geneyx and Omics Discoveries (Munich, Germany) to advance functional genomics through integrated DNA-RNA analysis. Geneyx Analysis AI-based genomic interpretation engine is combined with Omics Discoveries' RNA-seq technology to offer clinical geneticists an integrated view of DNA, RNA, and phenotype data. Expected commercial availability within six months of announcement.

Strategic tierStrategicTypeGTM or Marketing PartnerAnnounced on2024-09-19
Description

Geneyx was selected into Google's AI First Accelerator program - a 10-week program for AI-first startups in Europe and Israel. Benefits include Google Cloud credits, mentorship from Google Cloud and Google DeepMind, workshops on product design and business growth, and connections to venture capitalists and investors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-13
Description

Research collaboration through a Master Software Subscription and Services Agreement enabling Children's Mercy to use Geneyx Analysis for analyzing PacBio HiFi long-read sequencing data. Children's Mercy is the first healthcare system to use advanced genomic sequencing technology as first-line assessment for critically ill pediatric patients with suspected genetic disease. Geneyx provides genomic training, research, and analysis support.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-01
Description

Geneyx is listed as a PacBio Compatible tertiary analysis partner for HiFi long-read sequencing data on PacBio's Sequel II, Sequel IIe, and Revio systems. Geneyx enables PacBio customers to leverage HiFi data for rare and inherited disease research with features including phasing and methylation analysis. Partnership maximizes value of HiFi data and completes the end-to-end workflow for PacBio customers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-26
Description

Joint development partnership with Ocean Genomics (later renamed/partnership continued as Omics Discoveries) to develop multi-omic software combining DNA and RNA analysis for improved detection of genomic variants. Funded by the BIRD Foundation. The collaboration aims to enhance disease diagnosis and drug target identification through integrated DNA-RNA analysis. SVDuo product released as a result.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-09
Description

Strategic technology partnership to develop the first scalable end-to-end software solution for clinical reporting of nanopore sequencing data. Geneyx Analysis integrates with Oxford Nanopore's EPI2ME cloud platform for secondary-to-tertiary analysis workflow. The partnership includes pilot projects with Digi7 and Mediclinic Middle East. Target applications include newborn screening and rare/undiagnosed disease research.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-05-28
Description

Mediclinic Middle East partnered with Geneyx through Digi7 to implement AI-based genomic analysis at Mediclinic hospitals in Abu Dhabi and Dubai, UAE. Geneyx showcases its capabilities with a highly respected healthcare provider to gain feedback and establish market presence in the Middle East region.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Geneyx Analysis in Africa. Inqaba Biotec, based in South Africa, distributes and supports Geneyx Analysis across African markets, providing local sales, implementation, and customer support.

9Digi7
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distribution partner in the Middle East. Digi7 launched Geneyx AI-based solution at Mediclinic hospitals in Abu Dhabi and Dubai, UAE, serving as a local implementation and support partner.

geneyx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public clinical genomics interpretation platform offering SOPHiA DDM for hereditary disease, oncology, and pharmacogenomics. Directly comparable to Geneyx Analysis as a tertiary interpretation SaaS sold to hospitals and clinical labs, with overlapping modules (CNV/SV, ACMG classification, RNA analysis) and similar buyer personas.

TypeBroad incumbent
Description

QIAGEN's clinical genomics software business offering Ingenuity Variant Analysis, QCI Interpret, and QCI Precision Insights. A broad incumbent in tertiary analysis serving pharma, clinical labs, and academic customers with overlapping variant interpretation and clinical reporting capabilities.

TypeDirect peer
Description

Clinical AI genomics interpretation platform focused on rare disease diagnosis and hereditary cancer, with Fabric Enterprise and Fabric Clinical products. Directly comparable in use case (rare disease tertiary interpretation), AI-driven variant prioritization, and clinical reporting.

TypeDirect peer
Description

UK-based clinical genomic interpretation platform for rare disease and somatic cancer, sold into hospitals and national genomics programs. Directly comparable in ACMG-aligned variant classification, clinical reporting, and rare disease workflows, and a competing choice in NHS/UK procurements.

TypeEmerging player
Description

Heidelberg-based clinical genomics decision support for rare disease and oncology, including MH Guide and Dataome. Comparable as a clinical interpretation platform targeting hospitals and rare disease programs, with overlapping pharmacogenomics and somatic interpretation use cases.

TypeBroad incumbent
Description

Enterprise genomic and biomedical data analysis platform used by pharma, clinical labs, and consortia for NGS processing at scale. Overlaps with Geneyx in clinical and research genomics workflows, with broader scope across pharma R&D and a more infrastructure/data-platform positioning.

TypeEmerging player
Description

Cloud genomics and biomedical data platform serving pharma, consortia, and public health genomics with federated analysis capabilities. Comparable as a software platform for genomic data analysis and interpretation, with overlapping enterprise and academic buyer personas.

TypeRegional player
Description

European genomics and real-world data platform providing clinical interpretation, biobank analytics, and genomic data management. Comparable as a clinical genomics software vendor in Europe with overlapping rare disease and pharmacogenomics interpretation capabilities.

9BlueBee (acquired by Illumina)
TypeOthers
Description

Genomic data management and analysis platform originally independent, now part of Illumina's bioinformatics portfolio (including DRAGEN-related cloud offerings). Adjacent/complementary to Geneyx through the DRAGEN integration ecosystem, with comparable cloud NGS analysis use cases.

TypeOthers
Description

Not a direct software peer, but referenced here as a representative pharma/rare disease buyer ecosystem for clinical genomic interpretation tools. Listed for ecosystem context given Geneyx's stated focus on rare disease customers and pharma-adjacent translational research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Geneyx

Clinical Genomics Softwaregeneyx.com

Geneyx is an Israeli healthtech company that provides an AI-powered tertiary analysis platform for interpreting next-generation sequencing data, serving hospitals, clinical diagnostic labs, and academic medical centers across 36+ countries.

What Geneyx does

Geneyx Genomex Ltd. is a privately-held Israeli health technology company that develops Geneyx Analysis, an AI-powered tertiary analysis platform for interpreting next-generation sequencing (NGS) data including whole genome sequencing, whole exome sequencing, gene panels, and microarrays. The platform combines automated bioinformatics pipelines with machine learning-based variant prioritization that integrates phenotypic data (HPO terms) and curated literature, alongside ACMG-compliant classification. It supports both short-read sequencing via the embedded Illumina DRAGEN secondary pipeline and long-read sequencing from PacBio HiFi and Oxford Nanopore, with extensions into multi-omics DNA+RNA analysis (via the SVDuo/Ocean Genomics/Omics Discoveries collaboration), methylation analysis, phasing, and a pharmacogenomics module covering 87 genes and 321+ drugs.

The company operates a subscription-based enterprise SaaS model with both cloud and on-premise deployment, sold primarily through direct field sales to hospitals, clinical diagnostic laboratories, and academic medical centers, supplemented by regional distributors covering EMEA, APAC, LATAM, the Middle East (via Digi7), and Africa (via Inqaba Biotec). Customers enter Master Software Subscription and Services Agreements with annual billing, and multiple relationships are documented at 4-6 year tenure, including IRCCS Bambino Gesù (Italy, extended 6 years), University of Hong Kong, and Hospital Universitari Son Espases. The platform holds ISO 13485:2016, ISO/IEC 27001:2022, ISO 27799:2016, HIPAA, GDPR, UK NHS Data Security and Protection Toolkit, and Cyber Essentials certifications — a regulatory stack required for clinical procurement.

Geneyx is integrated as the official tertiary analysis partner for Oxford Nanopore (EPI2ME), PacBio (Sequel II/IIe/Revio Compatible program), and Illumina (DRAGEN), and was selected into the Google AI First Accelerator in 2024. The company has raised $6.5 million in seed funding (November 2021, Capri + Accenture Ventures), maintains offices in Herzliya (HQ), Wilmington DE, and Heerlen (Netherlands), and serves approximately 2,000 active users analyzing 500,000+ clinical cases across 36 countries. It operates with a lean headcount of 11-50 employees.

Geneyx firmographics

Firmographics
Name
Geneyx
Legal name
Geneyx Genomex Ltd.
Website
https://geneyx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Geneyx is an Israeli healthtech company that provides an AI-powered tertiary analysis platform for interpreting next-generation sequencing data, serving hospitals, clinical diagnostic labs, and academic medical centers across 36+ countries.
Ownership category
akta.pro rank

Geneyx industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Clinical genomics software
  • NGS data analysis
  • Variant interpretation platform
  • Pharmacogenomics analysis
  • Multi-omics interpretation

Where Geneyx is headquartered

Location

Headquarters

HQ city
Herzliya
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

Geneyx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Geneyx Analysis Software Subscriptions: Geneyx generates revenue through software subscription agreements (Master Software Subscription and Services Agreement) for access to the Geneyx Analysis platform. Customers include hospitals, clinical diagnostic companies, and academic institutions. The platform is offered as a cloud-based SaaS solution with on-premise capability.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualPlatform access with subscription-based pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Geneyx product offering

Product offering

Core offering

Geneyx develops and sells Geneyx Analysis, an AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of next-generation sequencing (NGS) data — including whole-genome sequencing (WGS), whole-exome sequencing (WES), gene panels, microarrays, and long-read (PacBio HiFi, Oxford Nanopore) data. The platform automates variant annotation, ACMG-based classification, phenotypic prioritization, multi-omics (DNA + RNA + methylation) interpretation, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.

Product overview

Geneyx offers a unified platform architecture centered on Geneyx Analysis as the core product, complemented by specialized modules including Geneyx MultiOmics for integrated DNA/RNA/epigenetics analysis, Long-Read Analysis for PacBio and Oxford Nanopore sequencing data, and Geneyx Pharmacogenomics covering 87 genes and 321+ drugs. The SVDuo module (co-developed with Ocean/Omics Discoveries) enables combined DNA and RNA analysis for enhanced structural variant detection. Geneyx Clinical Apps provides clinical interpretation services. All products share a common AI-powered annotation and visualization engine within Geneyx Analysis, which serves as the central platform for variant prioritization, filtering, interpretation, and clinical reporting across all sequencing modalities.

Differentiator

Problem solved

Functional benefit

Brands

  • Geneyx Analysis: AI-Based Genetic Data Analysis and Interpretation Solution for WGS, WES, Gene Panels, and Microarrays.
  • Geneyx Clinical Apps
  • Geneyx MultiOmics
  • SVDuo

Products and services

  • Geneyx Analysis AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of NGS data (WGS, WES, gene panels, microarrays, and long-read). Automates variant annotation, ACMG classification, phenotypic prioritization, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.
  • Geneyx MultiOmics Multi-omics analysis product that combines DNA, RNA, and epigenetics (methylation) data for enhanced variant detection and functional genomics interpretation, built jointly with Omics Discoveries.
  • Long-Read Analysis Long-read sequencing analysis product compatible with PacBio HiFi (Sequel II, IIe, Revio) and Oxford Nanopore data, supporting phasing, methylation analysis, and structural variant detection.
  • Geneyx Pharmacogenomics Comprehensive pharmacogenomics workflow covering 87 genes and 321+ drugs, aligned with CPIC and PharmGKB levels; provides drug metabolism interpretations and clinical recommendations for 13 CPIC Level A/B genes affecting 68+ commonly prescribed drugs.
  • Geneyx Clinical Apps Clinical interpretation services that deliver accurate, compliant, and signed clinical reports for healthcare providers, including pharmacogenomics reporting.
  • SVDuo Integrated DNA and RNA analysis software co-developed with Ocean Genomics/Omics Discoveries, designed to enhance genomic variant detection by revealing previously undetectable structural variants through combined DNA and RNA analysis.

Quantifiable outcome

  • Hospitals report analyzing up to 15,000 samples/year with Geneyx Analysis, up from 400 samples/year before adoption
  • +2 more outcomes

Companies that use Geneyx

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Geneyx technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability6 records

Feature12 records

Geneyx partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, strategic and minor.

  • Omics DiscoveriescoreStrategic or Co-development Partner · 30 October 2024Partnership between Geneyx and Omics Discoveries (Munich, Germany) to advance functional genomics through integrated DNA-RNA analysis. Geneyx Analysis AI-based genomic interpretation engine is combined with Omics Discoveries' RNA-seq technology to offer clinical geneticists an integrated view of DNA, RNA, and phenotype data. Expected commercial availability within six months of announcement.
  • Google (AI First Accelerator)strategicGTM or Marketing Partner · 19 September 2024Geneyx was selected into Google's AI First Accelerator program - a 10-week program for AI-first startups in Europe and Israel. Benefits include Google Cloud credits, mentorship from Google Cloud and Google DeepMind, workshops on product design and business growth, and connections to venture capitalists and investors.
  • Children's Mercy Kansas CitycoreStrategic or Co-development Partner · 13 March 2024Research collaboration through a Master Software Subscription and Services Agreement enabling Children's Mercy to use Geneyx Analysis for analyzing PacBio HiFi long-read sequencing data. Children's Mercy is the first healthcare system to use advanced genomic sequencing technology as first-line assessment for critically ill pediatric patients with suspected genetic disease. Geneyx provides genomic training, research, and analysis support.
  • PacBiocoreTechnology or Integration · 1 November 2023Geneyx is listed as a PacBio Compatible tertiary analysis partner for HiFi long-read sequencing data on PacBio's Sequel II, Sequel IIe, and Revio systems. Geneyx enables PacBio customers to leverage HiFi data for rare and inherited disease research with features including phasing and methylation analysis. Partnership maximizes value of HiFi data and completes the end-to-end workflow for PacBio customers.
  • Ocean GenomicscoreStrategic or Co-development Partner · 26 July 2023Joint development partnership with Ocean Genomics (later renamed/partnership continued as Omics Discoveries) to develop multi-omic software combining DNA and RNA analysis for improved detection of genomic variants. Funded by the BIRD Foundation. The collaboration aims to enhance disease diagnosis and drug target identification through integrated DNA-RNA analysis. SVDuo product released as a result.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 9 June 2023Strategic technology partnership to develop the first scalable end-to-end software solution for clinical reporting of nanopore sequencing data. Geneyx Analysis integrates with Oxford Nanopore's EPI2ME cloud platform for secondary-to-tertiary analysis workflow. The partnership includes pilot projects with Digi7 and Mediclinic Middle East. Target applications include newborn screening and rare/undiagnosed disease research.
  • Mediclinic Middle EastminorImplementation/ SI/ Consulting Partner · 28 May 2023Mediclinic Middle East partnered with Geneyx through Digi7 to implement AI-based genomic analysis at Mediclinic hospitals in Abu Dhabi and Dubai, UAE. Geneyx showcases its capabilities with a highly respected healthcare provider to gain feedback and establish market presence in the Middle East region.
  • Inqaba BiotecminorChannel Partner/ Reseller/ DistributorRegional distributor for Geneyx Analysis in Africa. Inqaba Biotec, based in South Africa, distributes and supports Geneyx Analysis across African markets, providing local sales, implementation, and customer support.
  • Digi7minorChannel Partner/ Reseller/ DistributorRegional distribution partner in the Middle East. Digi7 launched Geneyx AI-based solution at Mediclinic hospitals in Abu Dhabi and Dubai, UAE, serving as a local implementation and support partner.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Geneyx competitors and assessment

Company assessment

Direct peers

  • SOPHiA GENETICS: Public clinical genomics interpretation platform offering SOPHiA DDM for hereditary disease, oncology, and pharmacogenomics. Directly comparable to Geneyx Analysis as a tertiary interpretation SaaS sold to hospitals and clinical labs, with overlapping modules (CNV/SV, ACMG classification, RNA analysis) and similar buyer personas.
  • Fabric Genomics: Clinical AI genomics interpretation platform focused on rare disease diagnosis and hereditary cancer, with Fabric Enterprise and Fabric Clinical products. Directly comparable in use case (rare disease tertiary interpretation), AI-driven variant prioritization, and clinical reporting.
  • Congenica: UK-based clinical genomic interpretation platform for rare disease and somatic cancer, sold into hospitals and national genomics programs. Directly comparable in ACMG-aligned variant classification, clinical reporting, and rare disease workflows, and a competing choice in NHS/UK procurements.

Broad incumbents

  • QIAGEN Digital Insights (Ingenuity, QCI): QIAGEN's clinical genomics software business offering Ingenuity Variant Analysis, QCI Interpret, and QCI Precision Insights. A broad incumbent in tertiary analysis serving pharma, clinical labs, and academic customers with overlapping variant interpretation and clinical reporting capabilities.
  • DNAnexus: Enterprise genomic and biomedical data analysis platform used by pharma, clinical labs, and consortia for NGS processing at scale. Overlaps with Geneyx in clinical and research genomics workflows, with broader scope across pharma R&D and a more infrastructure/data-platform positioning.

Emerging players

  • Molecular Health: Heidelberg-based clinical genomics decision support for rare disease and oncology, including MH Guide and Dataome. Comparable as a clinical interpretation platform targeting hospitals and rare disease programs, with overlapping pharmacogenomics and somatic interpretation use cases.
  • Lifebit: Cloud genomics and biomedical data platform serving pharma, consortia, and public health genomics with federated analysis capabilities. Comparable as a software platform for genomic data analysis and interpretation, with overlapping enterprise and academic buyer personas.

Regional players

  • BC Platforms: European genomics and real-world data platform providing clinical interpretation, biobank analytics, and genomic data management. Comparable as a clinical genomics software vendor in Europe with overlapping rare disease and pharmacogenomics interpretation capabilities.

Others

  • BlueBee (acquired by Illumina): Genomic data management and analysis platform originally independent, now part of Illumina's bioinformatics portfolio (including DRAGEN-related cloud offerings). Adjacent/complementary to Geneyx through the DRAGEN integration ecosystem, with comparable cloud NGS analysis use cases.
  • BioMarin (genomic analytics adjacent): Not a direct software peer, but referenced here as a representative pharma/rare disease buyer ecosystem for clinical genomic interpretation tools. Listed for ecosystem context given Geneyx's stated focus on rare disease customers and pharma-adjacent translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Geneyx social profiles

Digital presence

Geneyx compliance and trust

Trust signal

Compliance7 records

Geneyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Geneyx leadership team

Management profile

Number of profiles

Profiles6 records

Geneyx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Geneyx funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Geneyx M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geneyx

What does Geneyx do?

Geneyx develops and sells Geneyx Analysis, an AI-based cloud and on-premise SaaS platform that performs tertiary analysis and clinical interpretation of next-generation sequencing (NGS) data — including whole-genome sequencing (WGS), whole-exome sequencing (WES), gene panels, microarrays, and long-read (PacBio HiFi, Oxford Nanopore) data. The platform automates variant annotation, ACMG-based classification, phenotypic prioritization, multi-omics (DNA + RNA + methylation) interpretation, and clinical report generation for hospitals, clinical diagnostic labs, and academic medical centers.

Is Geneyx a public or private company?

Geneyx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Geneyx founded?

Geneyx was founded in 2018. It employs 11 to 50 people.

Where is Geneyx based?

Geneyx is headquartered in Herzliya, Israel, in the Middle East region.

How does Geneyx make money?

One revenue line is on record: geneyx Analysis Software Subscriptions.

Who are Geneyx's main competitors?

Direct peers on record are SOPHiA GENETICS, Fabric Genomics and Congenica. Broad incumbents are QIAGEN Digital Insights (Ingenuity, QCI) and DNAnexus. Emerging players are Molecular Health and Lifebit. BC Platforms is listed as a regional player. Others are BlueBee (acquired by Illumina) and BioMarin (genomic analytics adjacent).

Does Geneyx have an API?

Yes. Geneyx Analysis provides API capabilities including a new endpoint to programmatically retrieve TSV files, enhancing integration with downstream tools and pipelines. Version 6.2 introduced improved API capabilities. Version 5.9 mentions that new API scripts are available with updated details to improve usability. External JSON files from DRAGEN special callers can be uploaded via the API.

What industry is Geneyx in?

Geneyx's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PressatGeneyx Joins UK Government G-Cloud 15 Framework, Expanding UK Access to AI-Powered Genomic AnalysisGeneyx Genomex Ltd. has been approved as a supplier on the UK Government's G-Cloud 15 framework, providing NHS organizations and public-sector genomic laboratories with a streamlined procurement route for its AI-driven genomic analysis platform. This inclusion enables eligible UK entities to access Geneyx's cloud-based software for multi-omics integration and complex sequencing data interpretation under the Procurement Act 2023. The move expands Geneyx's market access in the UK healthcare sector, building on its existing global user base of over 5,500 users across 55 countries.EIN PresswireOcean Genomics and Geneyx to Enrich Genomic Variant Detection to Better Diagnose Diseases and Identify Drug TargetsOcean Genomics and Geneyx announced they have been awarded a grant from the BIRD Foundation to develop a multi-omic software method that integrates DNA and RNA technologies. This joint project aims to improve the detection of genomic variants for better disease diagnosis and drug target identification. The collaboration seeks to advance personalized medicine by enabling tailored treatment plans based on individual genetic profiles.GeneyxBioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis » GeneyxIsraeli bioinformatics startup Geneyx announced it will integrate its software with Oxford Nanopore Technologies' Epi2Me cloud platform to automate long-read sequencing analysis and clinical reporting, following existing connections to Illumina and Pacific Biosciences. The firms will begin with pilot projects in clinical settings, with no commercial launch timetable given. Geneyx has about 130 paying customers and raised $6.5 million in seed funding in 2021.Business Wire BlogOxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore SequencingOxford Nanopore Technologies and Geneyx announced a partnership to develop the first scalable software for clinical nanopore sequencing analysis. The platform will integrate with EPI2ME and Geneyx's AI, targeting newborn screening and rare disease research. Pilot projects will evaluate the solution before commercial availability.PR NewswireIsraeli Technology Leading World Out of COVID-19 CrisisThe IMPROVATE Innovation Conference, held online and in Tel Aviv, brought together Israeli technology and innovation companies presenting solutions in tourism, MedTech, and distance learning for European government officials and investors. Former Bulgarian President Rosen Plevneliev encouraged Israeli firms to enter Eastern European and Balkan markets, citing significant investment planned for healthcare system upgrades with European and government funding available. Multiple Israeli companies, including Kamada, Zebra Medical Vision, Sivan, TempraMed Israel, Inovytec Medical Solutions, Geneyx, HT BioImaging, and Soapy, showcased advanced medical and hygiene technologies at the event.